MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
AcelRx Pharmaceuticals Operating Expenses 2011-2026 | ACRX
Annual Operating Expenses AcelRx Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 40.3 M | 49.7 M | 33.9 M | 36 M | 37 M | 36.7 M | 42.9 M | 36.2 M | 32.1 M | 20.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.7 M | 20.4 M | 36.5 M |
Quarterly Operating Expenses AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.5 M | 14.1 M | 14.3 M | 12.6 M | 11.6 M | 9.7 M | 7.97 M | 8.61 M | 8.55 M | 10.3 M | 12.6 M | 15.2 M | 13.6 M | 11.3 M | 12.9 M | 11.5 M | 9.27 M | 8.32 M | 10 M | 11.6 M | 12 M | 9.89 M | 12.3 M | 8.64 M | 7.62 M | 8.86 M | 8.18 M | 11.5 M | 9.7 M | 8.36 M | 7.17 M | 6.88 M | - | 5.81 M | 4.66 M | 3.54 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 3.54 M | 10.1 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.14 | -1.73 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
154 M | $ 2.63 | - | $ 1.38 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 4.19 | -1.64 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
558 M | $ 12.39 | 1.98 % | $ 634 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.56 | 0.07 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
107 M | $ 6.67 | -0.07 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 49.34 | -1.36 % | $ 1.61 B | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 1.22 | -8.65 % | $ 21.3 M |  China |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.69 | -0.88 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 6.96 | -0.43 % | $ 2.54 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.96 | -0.13 % | $ 55.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 5.14 | -0.77 % | $ 677 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.64 | -0.61 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
279 M | $ 26.04 | -0.12 % | $ 1.2 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 13.91 | -0.22 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | $ 0.44 | -2.36 % | $ 6.97 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.81 | -0.96 % | $ 18.9 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.79 | 5.63 % | $ 144 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 9.08 | -1.3 % | $ 645 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.54 | -2.13 % | $ 4.39 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.76 | 0.96 % | $ 235 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.63 | 3.22 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 8.97 | -0.54 % | $ 5.54 B | Canada |
 |
Veru
VERU
|
44 M | $ 2.13 | -1.84 % | $ 287 M | USA |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 1.63 | -0.61 % | $ 17 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 12.52 | -0.2 % | $ 15.2 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.37 | 0.37 % | $ 5.91 M | USA |